AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06429163 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Upper hypogastric plexus blockade
Description: At the beginning of the operation the camera is used to visualise the area of the promontorium. Next, a 1 mm laparoscopic puncture needle is inserted through a trocar in the suprapubic region and plunged into the upper part of the formed dome to a depth of no more than 1 cm. After positioning the needle retroperitoneally, an aspiration test is performed to prevent intravascular injection. Then, 20 ml of 0.2% ropivacaine diluted with physiological saline is slowly injected. At the end of the procedure, the retroperitoneal space swollen by the local anaesthetic is visualised in the promontorium.
Study NCT06333522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Patients will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively.
Study NCT06461455 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A multifocal for astigmatism contact lenses
Description: Investigational multifocal contact lenses for astigmatism
Study NCT06461455 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Samfilcon A multifocal for astigmatism contact lenses
Description: Commercially available multifocal contact lenses for astigmatism
Study NCT06461455 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based contact lens cleaning and disinfection system
Study NCT05231265 — intervention group
Intervention type: OTHER
Intervention: Walking task
Description: Treadmill walking task with study of fractal variability (complexity) for 10 minutes.
Study NCT04997109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APPLES-tele
Description: The APPLES-tele intervention is 5 weekly telehealth sessions of therapist-demonstrated tasks, delivered over a 6 week period. Infant participants wear a soft-constraint harness (C-Mitt) on their less affected arm for 6 hours per day, while their parent encourages them to use their more affected arm to complete play-based activities as instructed by the study therapist. As the infant experiences success, heavier objects are provided. During times when the C-Mitt is not worn, parents engage therapist-demonstrated bimanual play of increasing difficulty.
Study NCT04997109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-centered Approach (PCA) Support Intervention
Description: The PCA support intervention is 5 weekly telehealth sessions delivered over a 6 week period. The PCA curriculum includes 5 basic principles of positive parenting from Triple P: ensuring a safe engaging environment, creating a positive learning environment, using assertive discipline, having reasonable expectations, and looking after yourself as a parent. All of these elements, when taught to parents in an individualized manner, can help promote responsivity, structure and expectations that are tailored to their child's condition and developmental stage. In addition, a curriculum of CP-specific knowledge will address the challenges unique to parents of children with CP, such as understanding principles of infant learning of new movements, challenges and solutions for self-directed activity in infants with CP.
Study NCT04997109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will receive the usual care from being followed in high-risk infant follow-up (HRIF) programs in the Early Detection and Intervention (EDI) Network.
Study NCT06022965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive SOC
Study NCT06022965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive SOC
Study NCT06022965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Complete CARG-GA
Study NCT06022965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Geriatric Assessment
Description: Complete CARG-GA
Study NCT06022965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06022965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06022965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05231694 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EA intervention
Description: Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day.
Study NCT05231694 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: sham EA intervention
Description: The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
Study NCT04976309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG09222
Description: Single dose
Study NCT04976309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose
Study NCT04714554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix/E2/NETA FDC
Description: Relugolix/E2/NETA (40 mg/1 mg/0.5 mg) FDC tablet; oral administration.
Study NCT04714554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix 120-mg tablets; oral administration.
Study NCT06022965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06022965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive GA-based interventions
Study NCT06022965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Receive GA-based interventions via telemedicine
Study NCT05677100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortix System
Description: Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and are resistant to diuretic therapy.
Study NCT04714554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Erythromycin 500-mg tablets; oral administration.
Study NCT05248022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting beads bronchial arterial chemoembolization
Description: Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres can be loaded with vinorelbine, gemcitabine, irinote Kang, raltitrexed. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is vinorelbine 25mg/m2, gemcitabine generally 1000mg/m2, irinotecan 80mg/ m2, raltitrexed 4mg. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days.
Study NCT05248022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Programmed Cell Death Protein 1 Inhibitor
Description: Programmed cell death protein 1 inhibitor fixation was treated with sintilimab (Xinda Biopharmaceutical Co., Ltd.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
Study NCT06033521 — intervention group
Intervention type: DRUG
Intervention: Menopausal hormone therapy Intervention Type: Drug
Description: Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database
Study NCT05678894 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Scanner and EOS imaging
Description: Cross-sectional imaging and 3D reconstruction to measure and compare acetabular anteversion in 4 functional pelvic positions.
Study NCT05678894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scanner and EOS imaging
Description: Cross-sectional imaging and 3D reconstruction to measure and compare acetabular anteversion in 4 functional pelvic positions.
Study NCT05977582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spanish version eBodyProject
Description: The Spanish adaptation of the eBodyProject program will be modified (Stice et al., 2012b). This program consists of 4 modules adapted from the most recent version of the original program The Body Project, presented by the original authors who have given their consent and suggestions for the realization of the Spanish version.~The activities proposed through the different modules will be in written format or behavioral activities aimed at criticizing the ideal of feminine beauty imposed by today's society and promoting self-acceptance.
Study NCT05977582 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducationa Prevention Program
Description: Participants in this group will receive a weekly newsletter with information about the beauty ideal, the costs of pursuing it, and tips for resisting the pressure to pursue this ideal, as well as tips for managing the emotions associated with it. However, they will not have to perform exercises related to this information, a psychoeducational intervention. Once the study is finished, these participants will receive an email again in case they are interested in taking part in the eBodyProject prevention program.
Study NCT04993456 — intervention group
Intervention type: PROCEDURE
Intervention: Caridac surgery
Description: Cardiac surgery
Study NCT05108025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Powder
Description: Topical Powder mixed with diluent
Study NCT05108025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Topical Powder
Description: Placebo Topical Powder mixed with diluent
Study NCT06605313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQ-Kyrin-T Transcatheter Tricuspid Valve Repair System
Description: Transcathether Edge-to-Edge repair for tricuspid regurgitation with SQ-Kyrin-T Transcatheter Tricuspid Valve Repair System.
Study NCT06604286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: In this group, patients received 8 mg IM dexamethasone injection into the masseter muscle after impacted tooth surgery.
Description: 8 mg IM dexamethasone injection was given to the groups immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection in group 1 was made into the masseter muscle. injection; The margo anterior of the mandible was palpated and horizontally parallel to the occlusal level of the mandibular second molar tooth and 1 cm behind the margo anterior towards the mandibular ramus. Bone contact was not taken during the injection and the injection was made by taking negative aspiration.
Study NCT06604286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8 mg IM dexamethasone injection into the pterygoid cavity after impacted tooth surgery.
Description: 8 mg IM dexamethasone injection was given to the group immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection given to Group 2 was directed to the region between the margo anterior of the mandible and the raphe pterygomandibularis, 1 cm above the occlusal level of the mandibular 2nd molar tooth, and the direction of the syringe from the incisal top of the opposing mandibular canine tooth to this region, and then entering the pterygomandibular cavity.
Study NCT06606431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multileveled-community approach
Description: One-to-one delivered interaction at relational level (Interpersonal Relations, Volunteers) Socio-health interaction at personalized level (Social Work) Group delivered interaction for volunteers (Group Dynamics) Community-level interactions (Social Cohesion, Community Networks)
Study NCT06606496 — intervention group
Intervention type: DEVICE
Intervention: Bispectral index (BIS)
Description: The bispectral index (BIS) monitor is a quantitative electroencephalographic (EEG) device that is widely used to assess the hypnotic component of anaesthesia, especially when neuromuscular blocking drugs are used. If necessary, it may be necessary to increase or decrease MAC (minimum alveolar concentration) in the testosterone group according to the BIS monitoring value.
Study NCT04787744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET-directed Local Therapy using Surgery
Description: Surgery will be used to treat metastases.
Study NCT04787744 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-directed Local Therapy using Radiation
Description: Radiation therapy will be used to treat metastases.~Radiation options include:~1. Stereotactic body radiotherapy (SBRT) using 1-10 fractions~2. Conventionally fractionated radiotherapy using elective nodal radiotherapy and a simultaneous integrated boost to involved nodes~The selection of the form of metastasis-directed radiotherapy for each metastasis will be determined using shared decision-making between the treating physician and the Veteran.
Study NCT03593317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: The doses used in the study are the doses used in standard clinical practice. Initial dose is 25 mg/day until study end . The duration of treatment for each patient is 12 months.
Study NCT03593317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken once a day at the same time of day. The duration of treatment for each patient is 12 months.
Study NCT06638645 — intervention group
Intervention type: PROCEDURE
Intervention: VATS/RATS anatomical lung resection
Description: Perioperative care according to the ERAS protocol for lung surgery
Study NCT05554341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05554341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05554341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05554341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05554341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib Hydrochloride Monohydrate
Description: Given PO
Study NCT05554341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03876262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: 2mg tablets, encapsulated for blinding
Study NCT03876262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: 3mg tablets, encapsulated for blinding
Study NCT03876262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: 3mg tablets, encapsulated for blinding
Study NCT04787744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salvage Local Therapy for locally recurrent disease
Description: For Veterans who have a local recurrence in addition to oligorecurrent metastatic lesions, they will undergo salvage local therapy using brachytherapy, SBRT, surgery, cryotherapy or HIFU. The selection of modality of salvage local therapy will be determined using shared decision-making between the treating physician and Veteran.
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin, Histrelin, Leuprolide & Triptorelin
Description: Androgen deprivation therapy (ADT) using an LHRH agonist
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin, Histrelin, Leuprolide & Triptorelin
Description: Androgen deprivation therapy (ADT) using an LHRH agonist
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT + Nilutamide, Flutamide, & Bicalutamide
Description: ADT adding anti-androgen therapy to an LHRH agonist
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT + Nilutamide, Flutamide, & Bicalutamide
Description: ADT adding anti-androgen therapy to an LHRH agonist
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix & Relugolix
Description: ADT using an LHRH Antagonist.
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix & Relugolix
Description: ADT using an LHRH Antagonist.
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT + Docetaxel +/- prednisone
Description: Enhanced SST using chemohormonal therapy
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT + Docetaxel +/- prednisone
Description: Enhanced SST using chemohormonal therapy
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT + Abiraterone + Prednisone
Description: Enhanced SST using Abiraterone + Prednisone
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT + Abiraterone + Prednisone
Description: Enhanced SST using Abiraterone + Prednisone
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT + Abiraterone + Methylprednisolone
Description: Enhanced SST using Abiraterone + Methylprednisolone
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT + Abiraterone + Methylprednisolone
Description: Enhanced SST using Abiraterone + Methylprednisolone
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT + Apalutamide
Description: Enhanced SST using ADT + Apalutamide
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT + Apalutamide
Description: Enhanced SST using ADT + Apalutamide
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT + Enzalutamide
Description: Enhanced SST using ADT + Enzalutamide
Study NCT04787744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT + Enzalutamide
Description: Enhanced SST using ADT + Enzalutamide
Study NCT04787744 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate-directed Radiation for De novo oligometastatic prostate cancer
Description: Veterans in ARM 1 will receive prostate-directed RT only and NO treatment to any nodal or distant metastatic sites.~Acceptable dose/fractionations include 55 Gy in 20 fractions and 36 Gy in 6 fractions.~Veterans in ARM 2 should receive prostate-directed local therapy using radiotherapy or radical prostatectomy in addition to PET-directed local therapy to metastases.
Study NCT04787744 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prostate-directed Radiation for De novo oligometastatic prostate cancer
Description: Veterans in ARM 1 will receive prostate-directed RT only and NO treatment to any nodal or distant metastatic sites.~Acceptable dose/fractionations include 55 Gy in 20 fractions and 36 Gy in 6 fractions.~Veterans in ARM 2 should receive prostate-directed local therapy using radiotherapy or radical prostatectomy in addition to PET-directed local therapy to metastases.
Study NCT05205161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0466
Description: All patients will receive treatment with the investigational product AZD0466 via intravenous infusion.
Study NCT05615389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicinal Cannabis - C12T12
Description: Participants randomised to receive C12T12 Ruby Balanced Oil will commence with 0.008ml/kg/day (0.1 mg/kg/day THC) in two divided doses, and titrate up in four steps (increase by 0.008ml/kg/day every four days) over 16 days up to a maintenance dose of 0.04ml/kg/day (0.5mg/kg/day THC) in two divided doses, with a ceiling dose of 2ml/day (25mg/day THC) for participants weighing 50kg or more. The maintenance dose will then be continued from day 17 until day 42.~Down-titration will occur for 16 days after the end of study visit, in the reverse of the up-titration period.
Study NCT05615389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicinal Cannabis - C20T5
Description: Participants randomised to the C20T5 Ruby CBD Oil will receive a matched volume to the C12T12 arm during the up-titration, maintenance, and down-titration phases.
Study NCT06516614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Coach
Description: Sleep-promoting intervention consisting of 4 phone sessions to improve sleep duration and consistency.
Study NCT06516614 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education
Description: Participants will receive a a binder with educational information about diabetes and educational messages from the study team.